Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Fineline Cube Apr 21, 2026
Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab

Fineline Cube Apr 21, 2026
Company Drug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Fineline Cube Apr 21, 2026
Company Drug

Amgen’s Blincyto Secures New Indication Approval for B-ALL Consolidation Treatment in the US

Fineline Cube Jun 18, 2024

Amgen (NASDAQ: AMGN) has announced that its bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received...

Company Drug

MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma

Fineline Cube Jun 18, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company

AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer

Fineline Cube Jun 17, 2024

Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...

Company Drug

FDA Approves Broadened Use of BMS’ Next-Gen TKI Augtyro for Advanced Solid Tumors

Fineline Cube Jun 17, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Deals

CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally

Fineline Cube Jun 17, 2024

CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced...

Company Deals

Neusoft IntelliRay Secures Over RMB 100 Million in Series C Funding Round

Fineline Cube Jun 17, 2024

Neusoft IntelliRay Technology Co., Ltd, a medical technology company based in Shenyang, has successfully closed...

Company Deals Drug

Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories

Fineline Cube Jun 17, 2024

Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an...

Company Drug

CARsgen Therapeutics’ Saikaize and CT071 Show Strong Results in EHA Clinical Trials

Fineline Cube Jun 17, 2024

CARsgen Therapeutics, a biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 2171), has...

Company Drug

RemeGen’s Disitamab Vedotin Shows Positive Results in Phase III Trial for HER2 Positive Breast Cancer

Fineline Cube Jun 14, 2024

RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced positive results from...

Company Deals

AbbVie Strikes Deal with FutureGen for Global Rights to Next-Gen TL1A Antibody FG-M701

Fineline Cube Jun 14, 2024

AbbVie (NYSE: ABBV), a biopharmaceutical giant based in the US, has announced a licensing agreement...

Company Deals

BeiGene to Terminate Partnership with NewBridge Pharmaceuticals for MENA Region

Fineline Cube Jun 14, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China, has...

Company Deals

Ethypharm Expands in China’s IBD Market with Acquisition of Mesalazine Suppository

Fineline Cube Jun 14, 2024

Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has...

Company Deals

Sihuan’s Xuanzhu Biopharmaceutical Strikes Licensing Deal with Livzon Pharmaceutical for Fadanafil

Fineline Cube Jun 14, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co.,...

Company Drug

CStone Pharmaceuticals Gets NMPA Green Light for Local Production of Gavreto

Fineline Cube Jun 14, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has announced that it...

Company Drug

Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors

Fineline Cube Jun 14, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Deals

Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot

Fineline Cube Jun 14, 2024

Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3...

Company Deals Drug

Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization

Fineline Cube Jun 14, 2024

Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy...

Company Deals Medical Device

Zhejiang Dian Diagnostics Partners with Quest Diagnostics to Advance Alzheimer’s Disease Blood Tests

Fineline Cube Jun 14, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has...

Company Drug

Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic

Fineline Cube Jun 14, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership...

Company Deals

GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development

Fineline Cube Jun 14, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow...

Posts pagination

1 … 333 334 335 … 654

Recent updates

  • Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab
  • Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma
  • Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development
  • China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive
  • FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Company Drug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.